Monday, October 1, 2018
ACGT and Alexandria Real Estate Equities, Inc., invite you to an Intimate Conversation with Crystal Mackall, MD
In its most recent look at states where innovation and entrepreneurship rank high, the U.S. Department of Commerce Foundation rated Maryland third, highlighting the state as a “national leader in bioscience, biotechnology, and health innovation.”
WellSpan Health and Johns Hopkins Kimmel Cancer Center have partnered to launch a grant program to support cancer research.
The biotechnology industry in the Boston region, especially Cambridge, is a powerhouse even when compared with the innovation and development seen in the San Francisco Bay Area. These hubs function at a whole different level in biotech compared with other biotech clusters in the U.S. The healthy rivalry between San Francisco and Boston has fostered rapid growth in biotech thanks to their robust populations of small startups, large well-established pharmaceuticals, incubator sites, and large biotech-focused research institutions.
SparkLabs Group operates a network of accelerators and venture capital funds, and today it is adding to them with the creation of a new global accelerator program focused on cybersecurity and blockchain-related startups in Washington, D.C.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and Children’s National Health System, a pediatric academic medical center in Washington, have launched a clinical research partnership devoted to treating and preventing allergic, immunologic and infectious diseases in children. An inaugural symposium will take place at Children’s National on Sept. 17, 2018, to highlight the partnership and discuss current and future directions for its research activities.
Autolus Therapeutics is a promising clinical-stage biotech that is a leader in T-cell programming and manufacturing technology. They have seen rapid growth since launching in 2014, and recently executed a successful US IPO in June that raised $160.4M at a $17 share price and landed them on the Nasdaq (AUTL).
United Therapeutics Corporation announced that it has entered into an exclusive license agreement with privately held drug development company, Samumed LLC, for purchasing the North American rights to the latter’s IPF drug candidate, SM04646.
Principia Biopharma Inc. (Principia or the Company) (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the closing of its initial public offering of 7,187,500 shares of its common stock, including the exercise in full of the underwriters’ option to purchase 937,500 additional shares of common stock, at a public offering price of $17.00 per share. The gross proceeds to Principia, before deducting underwriting discounts and commissions and offering expenses, were approximately $122.2 million. All of the common stock was offered by Principia. Principia’s common stock is listed on The Nasdaq Global Select Market under the trading symbol “PRNB.”
Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced it has secured $150 million in a joint, oversubscribed Series C financing and royalty purchase agreement. The financing was led by new investor Clarus, with participation from additional new investors Adage Capital Management, HBM Healthcare Investments, Nan Fung Life Sciences, RA Capital, Rock Springs Capital and Tekla Capital Management LLC. Existing investors Correlation Ventures, Galera Angels, New Enterprise Associates, Novartis Venture Fund, Novo Ventures and Sofinnova Ventures also participated. In addition, Emmett T. Cunningham, Jr., M.D., Ph.D., MPH, Managing Director at Clarus, will join Galera’s Board of Directors.